Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data
暂无分享,去创建一个
Jihye Kim | Jaewoo Kang | Minjae Yoo | Jimin Shin | Karen A. Ryall | Aik Choon Tan | Trista K. Hinz | Lynn E. Heasley | Jaewoo Kang | Jihye Kim | A. Tan | L. Heasley | Minjae Yoo | Jimin Shin | K. Ryall | T. Hinz | A. Tan
[1] Mindy I. Davis,et al. Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.
[2] F. Hirsch,et al. The mTOR pathway in lung cancer and implications for therapy and biomarker analysis. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[3] Jaewoo Kang,et al. Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy , 2014, Bioinform..
[4] K. Flaherty,et al. TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma , 2013, Science Translational Medicine.
[5] Andrew P. Hodges,et al. Prediction of kinase inhibitor response using activity profiling, in vitro screening, and elastic net regression , 2013, BMC Systems Biology.
[6] F. Hirsch,et al. FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies , 2014, Clinical Cancer Research.
[7] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[8] Jihye Kim,et al. DSigDB: drug signatures database for gene set analysis , 2015, Bioinform..
[9] Jae Cheol Lee,et al. AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells. , 2015, Anticancer research.
[10] Theonie Anastassiadis,et al. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity , 2011, Nature biotechnology.
[11] N. Gray,et al. Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.
[12] Elena B. Pasquale,et al. Eph receptors and ephrins in cancer: bidirectional signalling and beyond , 2010, Nature Reviews Cancer.
[13] David Hsieh,et al. Inhibition of CK2α down-regulates Notch1 signalling in lung cancer cells , 2013, Journal of cellular and molecular medicine.
[14] Juthamas Sukbuntherng,et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.
[15] Yanli Wang,et al. PubChem BioAssay: 2014 update , 2013, Nucleic Acids Res..
[16] René Bernards,et al. Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. , 2014, Trends in biochemical sciences.
[17] N. Rosen,et al. mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer , 2013, Science Translational Medicine.
[18] B. Druker,et al. RNAi screen for rapid therapeutic target identification in leukemia patients , 2009, Proceedings of the National Academy of Sciences.
[19] B. Al-Lazikani,et al. Combinatorial drug therapy for cancer in the post-genomic era , 2012, Nature Biotechnology.
[20] Armand Bankhead,et al. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. , 2013, Cancer research.
[21] John Kuriyan,et al. Activation of tyrosine kinases by mutation of the gatekeeper threonine , 2008, Nature Structural &Molecular Biology.
[22] B. Manning,et al. mTORC1 Status Dictates Tumor Response to Targeted Therapeutics , 2013, Science Signaling.
[23] P. Zarrinkar,et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). , 2009, Blood.
[24] M. Rask-Andersen,et al. The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. , 2014, Annual review of pharmacology and toxicology.
[25] P. Qiu,et al. Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells , 2013, Oncotarget.
[26] George Papadatos,et al. The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..
[27] Ranadip Pal,et al. A new approach for prediction of tumor sensitivity to targeted drugs based on functional data , 2013, BMC Bioinformatics.
[28] Karen A. Ryall,et al. Systems biology approaches for advancing the discovery of effective drug combinations , 2015, Journal of Cheminformatics.
[29] P. Petronini,et al. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. , 2014, Biochemical pharmacology.
[30] L. Peshkin,et al. Exploiting polypharmacology for drug target deconvolution , 2014, Proceedings of the National Academy of Sciences.
[31] T. Golub,et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. , 2006, Cancer cell.
[32] C. Sawyers,et al. Targeted cancer therapy , 2004, Nature.
[33] M. Glickman,et al. Converting Cancer Therapies into Cures: Lessons from Infectious Diseases , 2012, Cell.
[34] Sridhar Ramaswamy,et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..
[35] Katherine R. Singleton,et al. Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC. , 2015, Cancer research.
[36] S. Ramaswamy,et al. Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.
[37] Rafael A Irizarry,et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.